Related references
Note: Only part of the references are listed.Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review
G. Fond et al.
ACTA PSYCHIATRICA SCANDINAVICA (2014)
Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
Mohammad-Reza Khodaie-Ardakani et al.
PSYCHIATRY RESEARCH (2014)
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Fang Liu et al.
SCHIZOPHRENIA RESEARCH (2014)
Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials
Seiya Miyamoto et al.
CURRENT OPINION IN PSYCHIATRY (2013)
Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials
Taro Kishi et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials
Taro Kishi et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials
Yuki Matsuda et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Imran B. Chaudhry et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review
Iris E. Sommer et al.
SCHIZOPHRENIA BULLETIN (2012)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment
Kenji Hashimoto
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht et al.
LANCET (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
Yuko Fujita et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine
Lin Zhang et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
G Chouinard et al.
SCHIZOPHRENIA RESEARCH (2005)
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
MF Green et al.
BIOLOGICAL PSYCHIATRY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
